Traws Pharma (NASDAQ:TRAW) Announces Quarterly Earnings Results

Traws Pharma (NASDAQ:TRAW) announced its quarterly earnings data on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.18, FiscalAI reports.

Traws Pharma Price Performance

Traws Pharma stock traded down $0.03 during trading hours on Friday, hitting $0.57. The stock had a trading volume of 76,075 shares, compared to its average volume of 110,422. The stock’s fifty day moving average is $0.73 and its two-hundred day moving average is $1.37. Traws Pharma has a 1-year low of $0.43 and a 1-year high of $3.27. The stock has a market capitalization of $8.65 million, a price-to-earnings ratio of -0.34 and a beta of 1.57.

Institutional Trading of Traws Pharma

Several institutional investors and hedge funds have recently made changes to their positions in TRAW. Two Sigma Investments LP raised its stake in Traws Pharma by 37.1% in the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after purchasing an additional 5,955 shares during the last quarter. Geode Capital Management LLC lifted its position in Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after buying an additional 18,213 shares during the period. State Street Corp acquired a new position in shares of Traws Pharma during the 4th quarter valued at about $29,000. XTX Topco Ltd lifted its stake in shares of Traws Pharma by 294.2% in the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after purchasing an additional 31,502 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in Traws Pharma during the fourth quarter worth approximately $175,000. 7.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on TRAW. Weiss Ratings downgraded Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. HC Wainwright reiterated a “negative” rating and set a $1.00 price target on shares of Traws Pharma in a research note on Thursday, June 18th. Citigroup downgraded shares of Traws Pharma to a “neutral” rating in a research report on Monday, June 15th. Wall Street Zen raised shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, LADENBURG THALM/SH SH lowered Traws Pharma from a “buy” rating to a “neutral” rating in a report on Monday, June 15th. Three research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Traws Pharma has a consensus rating of “Reduce” and a consensus target price of $1.00.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.